Internship
Posted on 3/13/2025
Develops therapies targeting disease-causing proteins
No salary listed
No H1B Sponsorship
Remote in USA
Candidates must be based in the U.S.
Upload your resume to see how it matches 8 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Arvinas develops therapies aimed at treating serious diseases caused by harmful proteins. The company uses a special technology called PROTAC® to create protein degraders that work by utilizing the body's natural system to eliminate these unwanted proteins. This approach allows for targeted treatment of conditions like cancer and neurodegenerative disorders. Unlike many other biopharmaceutical companies, Arvinas focuses specifically on the degradation of disease-causing proteins, which sets it apart in the biotechnology field. The goal of Arvinas is to enhance patient outcomes by offering effective therapies that tackle the root causes of debilitating diseases.
Company Size
201-500
Company Stage
IPO
Headquarters
New Haven, Connecticut
Founded
2013
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
– Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 degrader –NEW HAVEN, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that data from the first-in-human study evaluating single-ascending and multiple-ascending doses in healthy volunteers of ARV-102 will be presented at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™), April 1-5, 2025 in Vienna, Austria.ARV-102 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting leucine-rich repeat kinase 2 (LRRK2), a multifunctional protein that has been implicated in Parkinson’s disease and progressive supranuclear palsy.Presentation details are as follows:Session Title: First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ARV-102, a PROTAC LRRK2 Degrader, in Healthy Males (ID:1963)Session Type: Symposium: LRRK2, Alpha-Synuclein, Parkin: Diagnosis and Therapeutic Targets (ID:83)Date: Friday, April 4, 2025Lecture Time: 3:20 p.m. - 3:35 p.m. CETThe full abstract can be accessed via the AD/PD 2025 online interactive program.About ARV-102ARV-102 is an oral, brain penetrant investigational PROTAC designed to degrade Leucine-rich repeat kinase 2 (LRRK2) which is a large multidomain scaffolding kinase. Increased activity and expressions of LRRK2 have been implicated in the pathogenesis of neurological diseases including and Parkinson’s disease and progressive supranuclear palsy.About ArvinasArvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins
– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival –– Vepdegestrant is the first PROTAC degrader to demonstrate clinical benefitin a Phase 3 trial –NEW HAVEN, Conn. and NEW YORK, March 11, 2025 – Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer whose disease progressed following prior treatment with cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy. These are the first pivotal data for vepdegestrant, a potential first-in-class investigational oral PROteolysis TArgeting Chimera (PROTAC) ER degrader.The trial met its primary endpoint in the estrogen receptor 1-mutant (ESR1m) population, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to fulvestrant. The results exceeded the pre-specified target hazard ratio of 0.60 in the ESR1m population
In a corporate update, Arvinas announced the appointment of Alex Santini as interim Chief Commercial Officer, effective January 17, 2025.
Arvinas said it will also add 1,500 square feet of space at 5 Science Park for a total of 64,000 square feet.
Arvinas appoints Andrew Saik as CFO with equity incentives.